Home / Intelligence / Briefs / Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 and all new medicines from 2030.
The JCA process will run parallel to European Medicines Agency (EMA) regulatory evaluation and will involve submission of a dossier detailing disease information, product information and clinical data, but will not include economic data, which will be assessed later, at national level.
As JCA comes into effect, manufacturers will need to carefully consider their processes for development of global value/reimbursement dossiers to ensure that they continue to meet the needs of their affiliates in Europe and beyond.
Complete the form below to access the full advisory brief
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Briefs
Assessing the Influence of ICER Reports on U.S. Payer Decision Making
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product funding or pricing in the U.S. in the same way as, for example, National Institute […]
Read More
Webinars
Innovation in Value Strategy: Disrupting the Value Communication Landscape
Available On Demand
Working at the cutting edge of pricing and market access for innovative therapies launched over the last decade, Trinity Life Sciences has seen new diseases, technologies and decision drivers emerge. These have demanded the innovation and testing of new methods and concepts for communicating value to healthcare payers. In this webinar, we will briefly review the core, timeless principles […]
Watch Now
White Papers
Solving a Pervasive Challenge: Breaking Down Silos in Life Sciences
Experts at Trinity Life Sciences interact with the inner workings of pharma from many perspectives as they engage with teams across life sciences organizations. A common observation is that teams are working in silos: often unaware of what other teams are doing, sometimes pulling in different directions and frequently experiencing frustrations. Internally, siloed working can […]
Read More